We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News COVID-19 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology BioResearch Industry

Vitamin D Levels Tied to COVID-19 Risk for African-Americans

By LabMedica International staff writers
Posted on 29 Mar 2021
Vitamin D has diverse physiological effects, including on calcium regulation, bone density, and immune function. Deficient levels, typically defined as 25-hydroxyvitamin D (also known as calcifediol) level less than 20 ng/mL are common, especially in African-Americans individuals.

Vitamin D is also important for immune function, and a meta-analysis of randomized clinical trials using daily or weekly dosing has found vitamin D supplementation was associated with substantially decreased viral respiratory infections, especially in individuals who were deficient in vitamin D, but also individuals without a deficient level.

Image: A blood test for Vitamin D showed that African-Americans individuals with low Vitamin D were more at risk from COVID-19 (Photo courtesy of Getty Images)
Image: A blood test for Vitamin D showed that African-Americans individuals with low Vitamin D were more at risk from COVID-19 (Photo courtesy of Getty Images)

A team of Medical Scientists from The University of Chicago (Chicago, IL, USA) examined whether COVID-19 test results are associated with differences in vitamin D levels of 30 ng/mL or greater, including for White individuals and for African-Americans individuals. The team assessed data from 4,638 people tested for COVID-19 from March 3, 2020 to April 10, 2020, who also had data on vitamin D levels within a year prior to COVID-19 testing. COVID-19 status was determined by the Centers for Disease Control and Prevention or Viacor polymerase chain reaction (PCR, Lee's Summit, MO, USA) test used until in-house testing with the Cobas SARS-CoV-2 RT-PCR (Roche Diagnostics, Rotkreuz, Switzerland) began March 15, 2020.

The primary outcome was whether vitamin D level within 14 days was associated with testing positive for COVID-19, and the group controlled for time and vitamin D treatment changes since the vitamin D level was measured, as well as demographic characteristics and comorbidity indicators. The team reported that patients' mean age was around 53 and 69% were women; 49% were African-Americans and 43% were White. They were stratified into four groups by vitamin D levels. African-Americans individuals were more likely than White individuals to have vitamin D levels below 20 ng/mL (36% and 16%, respectively), and more likely to test positive for COVID-19 (9% and 5%, respectively). COVID-19 risk decreased by 5% for each 1 ng/mL increment among individuals with a level of 30 ng/mL or greater in African-Americans individuals.

The authors concluded that COVID-19 risk increased among African-Americans individuals with vitamin D level less than 40 ng/mL compared with those with 40 ng/mL or greater and decreased with increasing levels among individuals with levels greater than 30 ng/mL. No significant associations were noted for White individuals. The study was published on March 19, 2021 in the journal JAMA Network Open.

Related Links:
The University of Chicago
Viacor
Roche Diagnostics



Latest Clinical Chem. News